FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977631844> ?p ?o ?g. }

• W2977631844 endingPage "v522" @default.
• W2977631844 startingPage "v521" @default.
• W2977631844 abstract "Abstract Background New patterns of response to ICIs were recently described, including hyperprogressive disease (HPD) and pseudoprogression (PsPD). However, there is a lack of unanimous criteria about its definition. HPD predictors have not been identified. We aim to characterize predictive variables and related outcomes of patients (pts) treated with ICIs experiencing rapid tumor surge at our institution. Methods We performed a retrospective analysis of 210 pts treated with mono or dual ICI or ICI plus chemotherapy (CHT), from November 2013 to October 2018. Two CT scans before ICI and 1 CT scan while treatment was required and assessed according to RECIST 1.1. Tumor growth rate (TGR) at baseline, during ICI and its variation per month (ΔTGR) were calculated. HPD was defined as ΔTGR ≥ 2-fold. Overall survival (OS) and progression free survival (PFS) were estimated using the Kaplan-Meier method and compared between HPD and not HPD using the log-rank test. Results 187 pts were eligible, 23 pts died before tumor assessment. Mean age 63 (37-83), male 75%, performance status (PS) ≤1 88%. Non-small cell lung cancer (NSCLC) 62%, urothelial carcinoma 23% and kidney carcinoma 15%. Treated in phase3 31%. Two or more prior treatment lines (TL) 24%, ICI monotherapy 85% (nivolumab 49%, pembrolizumab 28%, atezolizumab 22%) and 11% combined with CHT. More than 3 metastatic sites 28%. At first evaluation 29 pts (15.5%) had progressive disease: 18 pts (10%) met HPD criteria; while 11 pts (6%) had ΔTGK Conclusions In our multitumor cohort, HPD occurs in 10% of pts treated with ICIs and is associated with worse OS, mostly in NSCLC. Further work is needed to better characterize this population. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure L. Ghiglione: Travel / Accommodation / Expenses: Kyowa Kirin; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Rovi; Travel / Accommodation / Expenses: Leo Pharma; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Lilly. C. Cabrera Galvez: Advisory / Consultancy: Pfyzer; Advisory / Consultancy: Roche ; Advisory / Consultancy: Boehringer ; Advisory / Consultancy: Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb. O. Reig: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Pfizer; Travel / Accommodation / Expenses: Ipsen. N. Vinolas: Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Boehringer Ingelheim; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Viphor Pharma; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Pierre Fabre. A. Prat: Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Nanostring Technology ; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Oncolytics Biotech ; Honoraria (self), Speaker Bureau / Expert testimony: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy: Puma ; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb. B. Mellado: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ipsen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb. N. Reguart: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche ; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ingelheim; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AbbVie; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis ; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Lilly ; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Aztra Zeneca ; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Guardiant Health ; Research grant / Funding (self): Instituto Carlos III ; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ipsen. All other authors have declared no conflicts of interest." @default.
• W2977631844 created "2019-10-10" @default.
• W2977631844 creator A5010040304 @default.
• W2977631844 creator A5020169038 @default.
• W2977631844 creator A5020674406 @default.
• W2977631844 creator A5023395087 @default.
• W2977631844 creator A5033765620 @default.
• W2977631844 creator A5052138653 @default.
• W2977631844 creator A5056477912 @default.
• W2977631844 creator A5057220121 @default.
• W2977631844 creator A5087391532 @default.
• W2977631844 creator A5089513581 @default.
• W2977631844 creator A5091733990 @default.
• W2977631844 date "2019-10-01" @default.
• W2977631844 modified "2023-10-18" @default.
• W2977631844 title "Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumours treated with immune checkpoint inhibitors (ICIs)" @default.
• W2977631844 doi "https://doi.org/10.1093/annonc/mdz253.108" @default.
• W2977631844 hasPublicationYear "2019" @default.
• W2977631844 type Work @default.
• W2977631844 sameAs 2977631844 @default.
• W2977631844 citedByCount "0" @default.
• W2977631844 crossrefType "journal-article" @default.
• W2977631844 hasAuthorship W2977631844A5010040304 @default.
• W2977631844 hasAuthorship W2977631844A5020169038 @default.
• W2977631844 hasAuthorship W2977631844A5020674406 @default.
• W2977631844 hasAuthorship W2977631844A5023395087 @default.
• W2977631844 hasAuthorship W2977631844A5033765620 @default.
• W2977631844 hasAuthorship W2977631844A5052138653 @default.
• W2977631844 hasAuthorship W2977631844A5056477912 @default.
• W2977631844 hasAuthorship W2977631844A5057220121 @default.
• W2977631844 hasAuthorship W2977631844A5087391532 @default.
• W2977631844 hasAuthorship W2977631844A5089513581 @default.
• W2977631844 hasAuthorship W2977631844A5091733990 @default.
• W2977631844 hasBestOaLocation W29776318441 @default.
• W2977631844 hasConcept C121608353 @default.
• W2977631844 hasConcept C126322002 @default.
• W2977631844 hasConcept C143998085 @default.
• W2977631844 hasConcept C2777701055 @default.
• W2977631844 hasConcept C2778822529 @default.
• W2977631844 hasConcept C2779134260 @default.
• W2977631844 hasConcept C2780851360 @default.
• W2977631844 hasConcept C71924100 @default.
• W2977631844 hasConcept C72563966 @default.
• W2977631844 hasConceptScore W2977631844C121608353 @default.
• W2977631844 hasConceptScore W2977631844C126322002 @default.
• W2977631844 hasConceptScore W2977631844C143998085 @default.
• W2977631844 hasConceptScore W2977631844C2777701055 @default.
• W2977631844 hasConceptScore W2977631844C2778822529 @default.
• W2977631844 hasConceptScore W2977631844C2779134260 @default.
• W2977631844 hasConceptScore W2977631844C2780851360 @default.
• W2977631844 hasConceptScore W2977631844C71924100 @default.
• W2977631844 hasConceptScore W2977631844C72563966 @default.
• W2977631844 hasLocation W29776318441 @default.
• W2977631844 hasOpenAccess W2977631844 @default.
• W2977631844 hasPrimaryLocation W29776318441 @default.
• W2977631844 hasRelatedWork W2315085516 @default.
• W2977631844 hasRelatedWork W2316407790 @default.
• W2977631844 hasRelatedWork W2584020663 @default.
• W2977631844 hasRelatedWork W2603773853 @default.
• W2977631844 hasRelatedWork W2885265774 @default.
• W2977631844 hasRelatedWork W2964295425 @default.
• W2977631844 hasRelatedWork W2999207890 @default.
• W2977631844 hasRelatedWork W4289517314 @default.
• W2977631844 hasRelatedWork W4307502331 @default.
• W2977631844 hasRelatedWork W4323664831 @default.
• W2977631844 hasVolume "30" @default.
• W2977631844 isParatext "false" @default.
• W2977631844 isRetracted "false" @default.
• W2977631844 magId "2977631844" @default.
• W2977631844 workType "article" @default.